TIRZEPATIDE
Information current as at: 1 April 2025
PBAC meeting date: November 2024
Submission Details
- Brand name:
-
- Mounjaro®
- Mounjaro® KwikPen®
- Pharmaceutical company:
- ELI LILLY AUSTRALIA PTY LTD
- Condition/indication:
(therapeutic use) -
- Diabetes mellitus type 2 (T2DM)
- PBAC Submission type:
- New PBS listing (Standard Re-entry Pathway)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – November 2024
- Related medicines:
Progress Details
-
Submission received for: - November 2024 PBAC meeting
-
Opportunity for consumer comment: - Open 31/07/2024 and close 25/09/2024 (see PBS Website)
-
PBAC meeting: - Held on 06/11/2024
-
PBAC outcome published: - Not Recommended (see PBAC Outcomes)
-
5Lodgement of required documentation:
- Has not yet commenced
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
Case ID: a965
Page last updated: 23 April 2025